Endpoint of Cancer Treatment: Targeted Therapies


Topcul M. R., Cetin I.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.11, pp.4395-4403, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 15 Issue: 11
  • Publication Date: 2014
  • Doi Number: 10.7314/apjcp.2014.15.11.4395
  • Journal Name: ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.4395-4403
  • Keywords: Cancer, cytotoxic chemotherapy, targeted therapy, FARNESYL TRANSFERASE INHIBITORS, STEM-CELLS, BREAST-CANCER, MONOCLONAL-ANTIBODIES, PROTEASOME INHIBITORS, KINASE INHIBITORS, RAF KINASE, GLUTATHIONE, MECHANISMS, METABOLISM
  • Istanbul University Affiliated: Yes

Abstract

Nowadays there are several limitations in cancer treatment. One of these is the use of conventional medicines which not only target cancer cells and thus also cause high toxicity precluding effective treatment. Recent elucidation of mechanisms that cause cancer has led to discovery of novel key molecules and pathways which have have become successful targets for the treatments that eliminate only cancer cells. These so-called targeted therapies offer new hope for millions of cancer patients, as briefly reveiwed here focusing on different types of agents, like PARP, CDK, tyrosine kinase, farnysyl transferase and proteasome inhibitors, monoclonal antibodies and antiangiogenic agents.